

Knowledge and Attitude towards Psychiatry among Nursing Staffs in Tertiary Health Care Hospital

Zilola Aramovna Djuraeva¹, Gulnora Siddiqovna Togaeva², Aziza Davranovna Davranova³

¹Assistant, Department of Endocrinology, Samarkand State Medical University, Samarkand, Republic of Uzbekistan.

²Assistant, Department of Endocrinology, Samarkand State Medical University, Samarkand, Republic of Uzbekistan, Orcid ID: 0000-0002-0478-037X, Email: gulnora.togaeva1981@mail.ru

³Assistant, Department of Endocrinology, Samarkand State Medical University, Samarkand, Republic of Uzbekistan. Orcid ID: 0000-0001-5479-6997, Email: aziza.davranova29@gmail.ru

Abstract

Type 2 diabetes mellitus (DM) is one of the most common noncommunicable diseases on the globe. If at present the number of patients with diabetes in the world is 347 million people, then by 2025, according to scientists, this figure will reach at least 592 million, of which 90% will be in diabetes. Global trends in the incidence of type 2 diabetes are also observed in Uzbekistan. The total number of patients with diabetes in Uzbekistan amounted to 230610 (706.24 per 100 thousand people), of which type 1 diabetes – 18349 (56.2 per 100 thousand people), type 2 diabetes – 212261 (650.0 per 100 thousand people). As a percentage, patients with type 1 diabetes of the total number of patients with diabetes is 8.0%, patients with type 2 diabetes are 92.0%. Maintaining a constantly normal or near normal concentration of glucose in the blood slows down the onset and progression of late complications of type 2 diabetes. In the absence of achieving the target glycemic values against the background of the use of a rational combination of oral hypoglycemic drugs, it is shown that baseline action is added to insulin treatment to suppress liver gluconeogenesis and normalize fasting glucose. The combination of sulfonylurea derivatives (PSM) and basal insulin has been well studied and has proven. In addition, the combined use of metformin and insulin was widely used in the treatment of patients with type 2 diabetes mellitus (T2DM), however, at present there is no evidence base in favor of their joint appointment.

Keywords: Glycemia, Metformin, Insulin, Basal Insulin.

Corresponding Author: Dr. Zilola Aramovna Djuraeva, Assistant, Department of Endocrinology, Samarkand State Medical University, Samarkand, Republic of Uzbekistan.

Received: 04 February 2022

Revised: 08 March 2022

Accepted: 20 March 2022

Published: 13 April 2022

Introduction

Objective is to study the efficacy and safety of the combined use of insulin and various doses of metformin to optimize the therapy of patients with type 2 diabetes mellitus.

Subjects and Methods

To compare the effectiveness of combined treatment with basal insulin and metformin at various doses and hypoglycemic therapy without metformin. To assess the risk of developing hypoglycemic conditions when prescribing hypoglycemic therapy without metformin and a combination of basal insulin (BI) with various doses of metformin. To study the dynamics of anthropometric parameters in patients with type 2 diabetes on against the background of the compared variants of hypoglycemic treatment. Conduct a comparative analysis of the dynamics of the state of lipid metabolism against the background of a combination of basal insulin with metformin at various doses and therapy without metformin. Determine the need for basal insulin against the background of the compared variants of hypoglycemic therapy. Conduct a pharmacoeconomic cost-effectiveness analysis patients receiving comparable antidiabetic treatment options. To achieve this goal, namely, to determine the feasibility of

combined administration of metformin and basal-acting insulin to patients with type 2 diabetes, among patients who were hospitalized at the Samarkand Regional Endocrinological Dispensary (SEED).

We selected 120 patients with DM2 who had not previously received insulin therapy (IT) and lipid-lowering drugs. Only 23.3% (n=28 out of 120) of patients before admission to the hospital received combination therapy with oral hypoglycemic drugs (OSSP), the remaining 76.7% of patients (n=92 out of 120) took only sulfonylurea derivatives (PSM), who were on inpatient treatment at the Samarkand Regional Endocrinological Dispensary (SEED). We selected 120 patients with DM2 who had not previously received insulin therapy (IT) and lipidlowering drugs. Only 23.3% (n=28 out of 120) of patients before admission to the hospital received combination therapy with oral hypoglycemic drugs (OHD), the remaining 76.7% of patients (n=92 out of 120) took only sulfonylurea derivatives (SD).

Results

Comparison of baseline characteristics of patients indicates that the duration of the disease was inadvertently longer in patients from groups 1 and 3. Perhaps this is the reason for the fact that in the first and third groups the number of

patients who required short-acting insulin was higher than in group 2.^[1,2,3]

The results of our study indicate that the correction of ongoing hypoglycemic therapy led to a significant decrease in fasting glycemia in all observed patients both after 6 months and after 1 year. When compared between groups of results obtained after 6 months, there was no statistically significant difference in fasting glycemia (FG). At the same time, when conducting an analysis after 1 year, it turned out that in patients from groups 1 and 2, GN was significantly lower compared to the same indicator in group 3, i.e., in patients who did not take metformin in addition to other hypoglycemic therapy (5.9 ± 0.5 vs. 6.5 ± 0.5 , $p < 0.001$ and 6.2 ± 0.7 vs. 6.5 ± 0.5 , $p < 0.05$). The reduction in GN resulted in an improvement in the overall glycemic profile and in a reduction in HbA1c in all treatment groups.^[4,5,6] A significant difference in indicators was revealed only when comparing the results between groups 1 and 3 after 1 year of follow-up ($7.40.4$ vs. $7.80.5$; $p < 0.001$). Thus, our data indicate that in patients taking metformin, regardless of its dose, GN decreased significantly more pronounced after 1 year compared to patients who did not take the drug. At the same time, a significant difference in HbA1c was recorded only in patients who received a higher dose of metformin (2000- 3000 mg/day). The results obtained indicate that a favorable effect on the glycemic profile as a whole was recorded only in patients taking metformin at a dose of 2000-3000 mg / day. in combination with insulin. When conducting an analysis in subgroups of patients who received SSM or CI in combination with other hypoglycemic therapy, it was found that the use of metformin at a dose of 2000-3000 mg / day. effectively reduces GN and HbA1c compared with the use of metformin at a dose of 500-1500 mg / day and monoinsulin therapy/PSM+BI therapy.^[7,8,9,10]

When conducting an analysis in subgroups of patients who received SSM or CI in combination with other hypoglycemic therapy, it was found that the use of metformin at a dose of 2000-3000 mg / day effectively reduces GN and HbA1c compared with the use of metformin at a dose of 500-1500 mg / day. monoinsulin therapy/PSM+BI therapy.^[11,12,13] Our data suggest that after 1 year the percentage of patients with HbA1c < 7.5% was significantly higher in the group of patients who received metformin at a dose of 2000-3000 mg per day as part of combination therapy, compared with the group of patients who did not receive metformin. (57% vs. 26%; $p < 0.01$).^[14,15] In addition, it should be emphasized that in 90.9% of patients (40 out of 44) from group 1, it was possible to achieve the target values of fasting glycemia. This indicator significantly differed from that in the groups of patients who took a lower dose of metformin (53.1% (17 of 32) % $2 = 10.3$; $p = 0.001$), and did not take metformin at all (50% (25 of 50) % $2 = 14.3$; $p < 0.001$).^[16,17]

Conclusion

1. The combined appointment of basal insulin and metformin at a dose of 2000 mg / day more effective than any hypoglycemic therapy without metformin in 79.5% of patients, it contributes to the achievement of compensation and subcompensation for type 2 diabetes.
2. The relative risk of developing mild hypoglycemia increases when metformin is combined with other hypoglycemic agents, the most dangerous of which are sulfonylurea derivatives prescribed in maximum daily doses.
3. Combination of basal insulin with metformin at a dose of 2000 mg/day. leads to a significantly smaller increase in body weight and waist circumference in patients with type 2 diabetes than any hypoglycemic therapy without metformin.
4. Dyslipidemia in patients with type 2 diabetes in 77.6% of cases is not corrected by the combined use of metformin with basal insulin and requires the appointment of adequate lipid-lowering therapy.
5. In patients with type 2 diabetes, the daily requirement for basal insulin when combined with metformin at a dose of 2000 mg / day 40% lower than without metformin.
6. Treatment of type 2 diabetes using metformin at a dose of 2000 mg / day. Together with basal insulin is more cost-effective than any hypoglycemic therapy without metformin.

References

1. Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, et al. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. *Blood*. 2018;131(25):2782– 2788. Available from: <https://doi.org/10.1182/blood-2018-01-826693>.
2. Wilcox G. Insulin and Insulin Resistance. *Clin Biochem Rev*. 2005;26(2):19–39.
3. Bailey CJ. Biguanides and NIDDM. *Diabetes Care*. 1992;15(6):755–772. Available from: <https://doi.org/10.2337/diacare.15.6.755>.
4. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The Metabolic Syndrome. *Endocr Rev*. 2008;29(7):777–822. Available from: <https://dx.doi.org/10.1210/er.2008-0024>.
5. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Ther Adv Cardiovasc Dis*. 2017;11(8):215–225. Available from: <https://dx.doi.org/10.1177/1753944717711379>.
6. Brunetti L, Kalabalik J. Management of Type-2 Diabetes Mellitus in Adults. *P T*. 2012;37(12):687–696.
7. Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. *Lancet* . 2011;377(9764):505–515. Available from: [https://dx.doi.org/10.1016/S0140-6736\(10\)61894-6](https://dx.doi.org/10.1016/S0140-6736(10)61894-6).
8. Laakso M. Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms. *Diabetes Care*. 2010;33(2):442–449. Available from: <https://dx.doi.org/10.2337/dc09-0749>.
9. Stuart RM, Khan O, Abey Suriya R, Kryvchun T, Lysak V, Bredikhina A, et al. Diabetes care cascade in Ukraine: an analysis of breakpoints and opportunities for improved diabetes outcomes. *BMC Health Serv Res*. 2020;20(1):409. Available from: <https://doi.org/10.1186/s12913-020-05261-y>.
10. Winiarska A, Filipka I, Knysak M, Stompór T. Dietary Phos-

phorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease. *Nutrients*. 2021;13(3):789. Available from: <https://dx.doi.org/10.3390/nu13030789>.

11. Agrawal P, Philip R, Saran S, Gutch M, Razi MS, Agroiya P, et al. Congenital hypothyroidism. *Indian J Endocrinol Metab*. 2015;19(2):221–227. Available from: <https://dx.doi.org/10.4103/2230-8210.131748>.
12. Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. *CMAJ*. 2005;172(2):213–226. Available from: <https://dx.doi.org/10.1503/cmaj.1031414>.
13. Colwell JA. Multifactorial aspects of the treatment of the type II diabetic patient. *Metabolism*. 1997;46(12):1–4. Available from: [https://doi.org/10.1016/s0026-0495\(97\)90308-5](https://doi.org/10.1016/s0026-0495(97)90308-5).
14. Suratovich OF, Siddikovna TG, Davranovna DA. Structural Features of Cells of the Islets of Langerhans in Offspring with Alloxonic Diabetes (Review Article). *Annals of RSCB*. 2021;25(1):158–162.
15. Suratovich OF, Siddikovna TG, Davranovna DA. Structural Features of Cells of the Islets of Langerhans in Offspring with Alloxonic Diabetes (Review Article). *Ann Romanian Soc Cell Biol*. 2021;25(1):158–162.
16. Djuraeva ZA, Rasulova SK, Mustafakulov IB. Biogeochemical Factors Affecting The Health Conditions Of The Mother And Child. *Int J Res*. 2020;7(4):578–584.
17. Spann SJ, Nutting PA, Galliher JM, Peterson KA, Pavlik VN, Dickinson LM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. *Ann Fam Med*. 2006;4(1):23–31. Available from: <https://doi.org/10.1370/afm.420>.

Copyright:© the author(s), 2022. It is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits authors to retain ownership of the copyright for their content, and allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited.

How to cite this article: Djuraeva ZA, Togaeva GS, Davranova AD. Knowledge and Attitude Towards Psychiatry among Nursing Staffs in Tertiary Health Care Hospital. *Adv Clin Med Res*. 2022;3(2): 4-6.

Source of Support: Nil, **Conflict of Interest:** None declared.